TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche.
暂无分享,去创建一个
M. Kitagawa | Toshiki Kawabata | H. Kikuchi | Masayoshi Yamamoto | Y. Hiramatsu | K. Kondo | Megumi Baba | M. Ohta | K. Kamiya | Tatsuo Tanaka | H. Konno
[1] V. Nomellini,et al. An age‐associated increase in pulmonary inflammation after burn injury is abrogated by CXCR2 inhibition , 2008, Journal of leukocyte biology.
[2] D. Nolan,et al. Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.
[3] M. Kitagawa,et al. ARA54 is involved in transcriptional regulation of the cyclin D1 gene in human cancer cells. , 2007, Carcinogenesis.
[4] T. Manabe,et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes , 2007, Oncogene.
[5] Ricky T. Tong,et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.
[6] Hiroyuki Aburatani,et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis , 2006, Nature Cell Biology.
[7] Judong Pan,et al. Stromal Derived Factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis , 2006, Molecular Cancer.
[8] Andrea Rosario Beccari,et al. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. , 2006, Pharmacology & therapeutics.
[9] R. Kerbel. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.
[10] S. Hwang,et al. Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.
[11] Hiroshi Yamamoto,et al. The secreted form of the p40 subunit of interleukin (IL)‐12 inhibits IL‐23 functions and abrogates IL‐23‐mediated antitumour effects , 2006, Immunology.
[12] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[13] T. Kubota,et al. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. , 2005, Oncology reports.
[14] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[15] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[16] Megumi Baba,et al. Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2. , 2003, Cancer letters.
[17] M. Burdick,et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.
[18] I. Fidler,et al. The organ microenvironment and cancer metastasis. , 2002, Differentiation; research in biological diversity.
[19] M. Shibuya,et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. , 2002, Cancer cell.
[20] P. Dhawan,et al. Role of CXCL1 in tumorigenesis of melanoma , 2002, Journal of leukocyte biology.
[21] A. Ullrich,et al. Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.
[22] Megumi Baba,et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. , 2002, Cancer letters.
[23] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[24] K. Pahan,et al. Induction of Nitric-oxide Synthase and Activation of NF-κB by Interleukin-12 p40 in Microglial Cells* , 2001, The Journal of Biological Chemistry.
[25] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[26] L. Ellis,et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. , 2001, Cancer research.
[27] M. Ohta,et al. Prevention of Hepatic and Peritoneal Metastases by the Angiogenesis Inhibitor FR‐118487 after Removal of Growing Tumor in Mice , 2001, Japanese journal of cancer research : Gann.
[28] Cherrington,et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.
[29] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[30] L. Ellis,et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. , 1999, Cancer research.
[31] Megumi Baba,et al. Antitumor Effect on Human Gastric Cancer and Induction of Apoptosis by Vascular Endothelial Growth Factor Neutralizing Antibody , 1999, Japanese journal of cancer research : Gann.
[32] D. Hicklin,et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.
[33] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[34] C. Bucana,et al. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. , 1997, The American journal of pathology.
[35] Tatsuo Tanaka,et al. Efficacy of an angiogenesis inhibitor, TNP‐470, in xenotransplanted human colorectal cancer with high metastatic potential , 1996, Cancer.
[36] Ann Richmond,et al. HMGI(Y) and Sp1 in addition to NF-κB regulate transcription of the MGSA/GROα gene , 1995 .
[37] Tatsuo Tanaka,et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP‐470, and mitomycin c on the growth and liver metastasis of human colon cancer , 1995, International journal of cancer.
[38] H. Konno,et al. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. , 1995, Cancer research.
[39] C. Geczy,et al. Acute inflammatory activity of the S100 protein CP-10. Activation of neutrophils in vivo and in vitro. , 1994, Journal of immunology.
[40] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] W. Wood,et al. Characterization of two high affinity human interleukin-8 receptors. , 1992, The Journal of biological chemistry.
[42] S. Paget. The distribution of secondary growths in cancer of the breast. 1889. , 1989, Cancer metastasis reviews.
[43] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[44] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[45] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.